{"preliminary_commentary":{"by_channel":{"podcast":7,"x_thread":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03239340\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ELIOS","nct_id":"NCT03239340","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=elios-nct03239340. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ELIOS","arms":[{"description":"An oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer","label":"Osimertinib","type":"EXPERIMENTAL"}],"collaborators":["Parexel"],"completion_date":{"date":"2023-09-19","type":"ACTUAL"},"conditions":["EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer"],"enrollment":{"count":154,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Osimertinib","otherNames":["TAGRISSO, AZD9291"],"type":"DRUG"}],"last_update":"2024-10-21","lead_sponsor":"AstraZeneca","official_title":"A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-09-19","type":"ACTUAL"},"primary_outcomes":[{"measure":"Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression","timeFrame":"Genetic and proteomic markers were assessed at baseline and progression (up to 5 years after baseline)"}],"references":[],"start_date":{"date":"2018-05-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib","url":"https://clinicaltrials.gov/study/NCT03239340"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/elios-nct03239340"}